{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:42:44Z","timestamp":1740148964697,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12325-021-01646-5","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T16:03:04Z","timestamp":1615824184000},"page":"2249-2270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and Safety of COPD Maintenance Therapy with\u00a0Tiotropium\/Olodaterol versus LABA\/ICS in a US Claims Database"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct04138758","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jennifer K.","family":"Quint","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Montonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daina B.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Koerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"de la Hoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"1646_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/11\/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 15 June 2020"},{"key":"1646_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/COPD.S62750","volume":"9","author":"D Price","year":"2014","unstructured":"Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889\u2013904.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12931-017-0683-x","volume":"18","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respir Res. 2017;18(1):196.","journal-title":"Respir Res"},{"issue":"11","key":"1646_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.arbres.2018.03.021","volume":"54","author":"JL Izquierdo","year":"2018","unstructured":"Izquierdo JL, Miravitlles M, Esquinas C, et al. Characteristics of COPD patients managed in respiratory medicine departments in Spain, according to GOLD groups and GesEPOC clinical phenotypes. Arch Bronconeumol. 2018;54(11):559\u201367.","journal-title":"Arch Bronconeumol"},{"issue":"9","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"1646_CR6","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. https:\/\/www.nice.org.uk\/guidance\/ng115\/chapter\/Recommendation. Accessed 15 June 2020.","DOI":"10.12968\/bjca.2020.0121"},{"key":"1646_CR7","doi-asserted-by":"publisher","first-page":"16068","DOI":"10.1038\/npjpcrm.2016.68","volume":"26","author":"BP Yawn","year":"2016","unstructured":"Yawn BP, Suissa S, Rossi A. Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med. 2016;26:16068.","journal-title":"NPJ Prim Care Respir Med"},{"key":"1646_CR8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2147\/COPD.S207775","volume":"14","author":"S Avdeev","year":"2019","unstructured":"Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019;14:1267\u201380.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"1646_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1183\/13993003.00282-2015","volume":"46","author":"S Suissa","year":"2015","unstructured":"Suissa S, Rossi A. Weaning from inhaled corticosteroids in COPD: the evidence. Eur Respir J. 2015;46(5):1232\u20135.","journal-title":"Eur Respir J"},{"issue":"7","key":"1646_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.rmed.2012.03.008","volume":"106","author":"A Corrado","year":"2012","unstructured":"Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989\u201397.","journal-title":"Respir Med"},{"issue":"1","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2466-14-56","volume":"14","author":"N Roche","year":"2014","unstructured":"Roche N, Pribil C, Van Ganse E, et al. Real-life use of fluticasone propionate\/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study. BMC Pulm Med. 2014;14(1):56.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"1646_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2296-15-42","volume":"15","author":"E Drivenes","year":"2014","unstructured":"Drivenes E, \u00d8strem A, Melbye H. Predictors of ICS\/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract. 2014;15(1):42.","journal-title":"BMC Fam Pract"},{"issue":"10","key":"1646_CR13","doi-asserted-by":"publisher","first-page":"e75221","DOI":"10.1371\/journal.pone.0075221","volume":"8","author":"P White","year":"2013","unstructured":"White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids\u2014implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221.","journal-title":"PLoS One"},{"key":"1646_CR14","doi-asserted-by":"publisher","first-page":"147997311986794","DOI":"10.1177\/1479973119867949","volume":"16","author":"O Savran","year":"2019","unstructured":"Savran O, Godtfredsen N, Sorensen T, Jensen C, Ulrik CS. COPD patients prescribed inhaled corticosteroid in general practice: based on disease characteristics according to guidelines? Chron Respir Dis. 2019;16:1479973119867949.","journal-title":"Chron Respir Dis"},{"issue":"2","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/fampra\/cmn006","volume":"25","author":"AEM Lucas","year":"2008","unstructured":"Lucas AEM, Smeenk FWJM, Smeele IJ, Van Schayck CP. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract. 2008;25(2):86\u201391.","journal-title":"Fam Pract"},{"issue":"3","key":"1646_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11606-019-05461-1","volume":"35","author":"MF Griffith","year":"2020","unstructured":"Griffith MF, Feemster LC, Zeliadt SB, et al. Overuse and misuse of inhaled corticosteroids among veterans with COPD: a cross-sectional study evaluating targets for de-implementation. J Gen Intern Med. 2020;35(3):679\u201386.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"1646_CR17","first-page":"CD010115","volume":"10","author":"KM Kew","year":"2014","unstructured":"Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;10(3):CD010115.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1646_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1164\/rccm.200611-1630OC","volume":"176","author":"P Ernst","year":"2007","unstructured":"Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"1646_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CEOR.S65824","volume":"6","author":"J Lin","year":"2014","unstructured":"Lin J, Li Y, Tian H, et al. Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia. Clinicoecon Outcomes Res. 2014;6:349\u201356.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"10","key":"1646_CR20","doi-asserted-by":"publisher","first-page":"e75887","DOI":"10.1371\/journal.pone.0075887","volume":"8","author":"M Ryan","year":"2013","unstructured":"Ryan M, Suaya JA, Chapman JD, Stason WB, Shepard DS, Thomas CP. Incidence and cost of pneumonia in older adults with COPD in the United States. PLoS One. 2013;8(10):e75887.","journal-title":"PLoS One"},{"issue":"10","key":"1646_CR21","first-page":"1363","volume":"26","author":"SR Palli","year":"2020","unstructured":"Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J. Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium\/olodaterol versus triple therapy. J Manag Care Spec Pharm. 2020;26(10):1363\u201374.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"1646_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1513\/AnnalsATS.202001-023OC","volume":"17","author":"MJ Mammen","year":"2020","unstructured":"Mammen MJ, Lloyd DR, Kumar S, et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for COPD: a systematic review and meta-analysis. Ann Am Thorac Soc. 2020;17(10):1308\u201310.","journal-title":"Ann Am Thorac Soc"},{"key":"1646_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17512433.2020.1817739","volume":"13","author":"P Rogliani","year":"2020","unstructured":"Rogliani P, Ritondo BL, Gabriele M, Cazzola M, Calzetta L. Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Rev Clin Pharmacol. 2020;13:977\u201390.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"1646_CR24","doi-asserted-by":"publisher","first-page":"2000351","DOI":"10.1183\/13993003.00351-2020","volume":"55","author":"JD Chalmers","year":"2020","unstructured":"Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020;55(6):2000351.","journal-title":"Eur Respir J"},{"key":"1646_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/COPD.S95055","volume":"11","author":"KM Beeh","year":"2016","unstructured":"Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat\u00ae is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler\u00ae (ENERGITO\u00ae study). Int J Chron Obstruct Pulmon Dis. 2016;11:193\u2013205.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1646_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2147\/COPD.S130482","volume":"12","author":"GJ Rodrigo","year":"2017","unstructured":"Rodrigo GJ, Price D, Anzueto A, et al. LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907\u201322.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1646_CR27","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2147\/COPD.S138006","volume":"12","author":"SM Tariq","year":"2017","unstructured":"Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA\/LABA inhalers? Int J Chron Obstruct Pulmon Dis. 2017;12:1877\u201382.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1646_CR28","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2147\/COPD.S134618","volume":"12","author":"JJ Stephenson","year":"2017","unstructured":"Stephenson JJ, Wertz D, Gu T, Patel J, Dalal AA. Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting. Int J Chron Obstruct Pulmon Dis. 2017;12:1947\u201359.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1646_CR29","first-page":"2055","volume":"10","author":"F Trudo","year":"2015","unstructured":"Trudo F, Kern DM, Davis JR, et al. Comparative effectiveness of budesonide\/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 2015;10:2055\u201366.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1646_CR30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/COPD.S108967","volume":"11","author":"X Ke","year":"2016","unstructured":"Ke X, Marvel J, Yu T-C, et al. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1689\u2013703.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1646_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2147\/COPD.S64491","volume":"9","author":"DM Kern","year":"2014","unstructured":"Kern DM, Williams SA, Tunceli O, et al. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:775\u201383.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"1646_CR32","first-page":"205","volume":"25","author":"AE Wallace","year":"2019","unstructured":"Wallace AE, Kaila S, Bayer V, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25(2):205\u201317.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1646_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chest.2016.08.001","volume":"151","author":"S Suissa","year":"2017","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study. Chest. 2017;151(1):60\u20137.","journal-title":"Chest"},{"issue":"2","key":"1646_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","volume":"28","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Rothman KJ, Bateman BT, Hernandez-Diaz S, Huybrechts KF. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017;28(2):249\u201357.","journal-title":"Epidemiology"},{"issue":"23","key":"1646_CR35","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222\u201334.","journal-title":"N Engl J Med"},{"issue":"14","key":"1646_CR36","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285\u201394.","journal-title":"N Engl J Med"},{"key":"1646_CR37","first-page":"1015","volume":"10","author":"N Zhong","year":"2015","unstructured":"Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol\/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015\u201326.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"1646_CR38","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1183\/13993003.00216-2016","volume":"48","author":"C Vogelmeier","year":"2016","unstructured":"Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium\/formoterol versus salmeterol\/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030\u20139.","journal-title":"Eur Respir J"},{"issue":"4","key":"1646_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/phar.1913","volume":"37","author":"JC Samp","year":"2017","unstructured":"Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. Comparative effectiveness of long-acting beta2-agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease. Pharmacotherapy. 2017;37(4):447\u201355.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1646_CR40","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.chest.2019.03.005","volume":"155","author":"S Suissa","year":"2019","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158\u201365.","journal-title":"Chest"},{"issue":"11","key":"1646_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-2600(18)30368-0","volume":"6","author":"S Suissa","year":"2018","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855\u201362.","journal-title":"Lancet Respir Med"},{"issue":"18","key":"1646_CR42","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"issue":"1","key":"1646_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"1646_CR44","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1185\/03007995.2012.743459","volume":"28","author":"J Thornton Snider","year":"2012","unstructured":"Thornton Snider J, Luna Y, Wong KS, et al. Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin. 2012;28(12):1959\u201367.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1646_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.rmed.2012.04.008","volume":"106","author":"H Mullerova","year":"2012","unstructured":"Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124\u201333.","journal-title":"Respir Med"},{"issue":"2","key":"1646_CR46","doi-asserted-by":"publisher","first-page":"00031","DOI":"10.1183\/23120541.00031-2019","volume":"5","author":"LJ Finney","year":"2019","unstructured":"Finney LJ, Padmanaban V, Todd S, Ahmed N, Sarah LE, Mallia P. Validity of the diagnosis of pneumonia in hospitalised patients with COPD. ERJ Open Res. 2019;5(2):00031\u20132019.","journal-title":"ERJ Open Res"},{"key":"1646_CR47","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2147\/COPD.S204649","volume":"14","author":"C Moretz","year":"2019","unstructured":"Moretz C, Sharpsten L, Bengtson LG, et al. Real-world effectiveness of umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01646-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01646-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01646-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T02:39:26Z","timestamp":1675046366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01646-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01646-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}